This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
POLARIS (PalbOciLib in HR+ Advanced Breast Cancer – a Multicenter, Prospective, NonInterventional Study) included patients with HR+/HER2- mBC who received treatment with IBRANCE from 110 community and academic centers in the US and Canada (N=1500).¹,²
* Case report forms recorded clinical and treatment data from patients’ existing medical charts.
The interim analysis included the first 522 US patients who completed ≥6 months of IBRANCE treatment as of May 20, 2019.²
75% of enrolled patients received IBRANCE in the first-line setting, and 25% as second or later line.²
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023